Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Targeting KIR Opens Door to Promising Immunotherapy Combos

December 30th 2016

Although T cells have commanded most of the attention in the burgeoning immuno-oncology field, there is a growing appreciation that other immune cells have important roles in tumor surveillance and would represent attractive therapeutic targets.

Give Precision Medicine a Chance

December 28th 2016

Negative reports evaluating molecularly selected agents should not derail the process of developing future therapies by employing a precision medicine approach.

Metabolic Pathways May Lead Researchers to Novel Therapeutic Targets in Neuro-Oncology

December 26th 2016

In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.

Emerging PD-L1 Inhibitors for HNSCC

December 22nd 2016

Ongoing Research of Immunotherapy in HNSCC

December 22nd 2016

Patient Selection for Nivolumab in HNSCC

December 22nd 2016

Nivolumab-Related Efficacy and Toxicity in HNSCC Patients

December 22nd 2016

Nivolumab: A New Standard-of-Care

December 22nd 2016

Immunotherapy for Recurrent HNSCC

December 22nd 2016

The Approval of Pembrolizumab for Recurrent HNSCC

December 22nd 2016

Immunotherapy for Virally Induced vs High-Mutation Burden HNSCC

December 22nd 2016

Mechanisms of Immunotherapy in HNSCC

December 22nd 2016

Historic Perspective on Recurrent HNSCC

December 22nd 2016

Historic Perspective on Systemic Therapy for Advanced HNSCC

December 22nd 2016

Multimodality Treatment for HNSCC

December 22nd 2016

Risk Stratification for HNSCC

December 22nd 2016

Biology of Head and Neck Squamous Cell Cancer (HNSCC)

December 22nd 2016

The Future of Driver Mutations in NSCLC

December 22nd 2016

Practical Experience With Dabrafenib/Trametinib in NCSLC

December 22nd 2016

Targeted Approaches in NSCLC: Lessons from Melanoma

December 22nd 2016